Immunome Inc. (IMNM)
Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: United States
Exchange: NASDAQ
Market cap: $2.72B
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
Latest financial period: June 30, 2026
Filed with the SEC: August 11, 2026
Estimated earnings date: November 5, 2026
Profit #1454 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROE/ROA | 1.5% | 2.5% | 1.1% | 0.8% |
Growth #1440 of 1484 companies
Payout #1117 of 1484 companies
Safety #713 of 1484 companies
Price #1448 of 1484 companies
